TCG Crossover
VC Fund
Palo Alto, United States
TCG Crossover is a VC fund in Palo Alto focused on Biotechnology and Health Care. TCG X is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCG X invests in both private and public companies led by exceptional entrepreneurs focused on developing better treatment options for patients. TCG X has investment teams in Palo Alto and New York City
- Total investments:
- 87
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries TCG Crossover invests in
Stages TCG Crossover invests in
Countries TCG Crossover invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chen Yu
|
|||
Investment Focus
Industry
- Biotechnology 70 (80%)
- Health Care 45 (52%)
- Therapeutics 35 (40%)
- Medical 32 (37%)
- Pharmaceutical 26 (30%)
Stage
- Post-IPO Equity 45 (52%)
- Series B 18 (21%)
- Series C 9 (10%)
- Series A 8 (9%)
- Series D 1 (1%)
Country
- United States 57 (66%)
- United Kingdom 6 (7%)
- China 4 (5%)
- France 2 (2%)
- Denmark 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Chen Yu
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 14 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tarsus Pharmaceuticals
|
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases acrosstherapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis. | $125M / Post-IPO Equity / Aug 06, 2026 | |
Obsidian Therapeutics
|
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with newfunctions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies. | $350M / Post-IPO Equity / Aug 04, 2026 | |
Entera Bio
|
Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience andnetworks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience. | $275M / Post-IPO Equity / Jul 27, 2026 | |
Agenus
|
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. The company's treatment aims to stimulate the immune system to recognize and fight cancer cells. Its goal is to treat cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers,vaccines, and adjuvants. In addition to a broad portfolio, the company has an accomplished team of scientists, novel technology platforms, and fully-integrated end-to-end capabilities from discovery to GMP manufacturing.It was established in 1994 and is headquartered in Lexington, Massachusetts. | $85M / Post-IPO Debt / Jul 13, 2026 | |
Ollin Biosciences
|
Ollin Biosciences operates as a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. | $330M / Series B / Jun 24, 2026 | |
Accro Bioscience
|
Accro Bioscience research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis. | $50M / Series C / May 18, 2026 | |
InflaRx
|
InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.In April 2018, InflaRx conducted a USD 117 million totalgross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany. | $150M / Post-IPO Equity / May 06, 2026 | |
Valneva
|
Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $43.1M / Post-IPO Equity / Apr 30, 2026 | |
Altimmune
|
Altimmune is an emerging biotechnology company located in Montgomery County, MD. Altimmune develops vaccines and other biological products to address unmet market and public health needs. The company uses a proprietary technology for non-invasive intranasal delivery, and has shown proof of principle in animals and in initial human clinical studies.Vaxin Inc., formerly known as Vaxin Pharmaceuticals and ImmuneFocus Corporation, was founded in 1997 by Emerging Technology Partners. Early experiments revealed that DNA incorporated into an adenovirus can elicit an immune response when placed on the surface of the skin, and subsequently research was expanded to include applications on the skin in the nose as well as experimentation with other vectors. | $225M / Post-IPO Equity / Apr 22, 2026 | |
ADCendo
|
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $75M / Series C / Apr 14, 2026 | |
| See all 87 investments → | |||
Co-Investors
RA Capital Management
32 deals together
Venrock Healthcare Capital Partners
27 deals together
Logos Capital
23 deals together
OrbiMed
22 deals together
Deep Track Capital
20 deals together
Surveyor Capital
17 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does TCG Crossover invest in?
TCG Crossover invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 87 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact TCG Crossover?
Public channels for TCG Crossover include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at TCG Crossover?
The team at TCG Crossover includes Chen Yu (Founder & Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
